DUBLIN--(BUSINESS WIRE)--Jan. 13, 2014--
Alkermes
plc (NASDAQ: ALKS) (Alkermes) today announced that it has entered
into a definitive purchase agreement with Invesco Perpetual Income Fund
and Invesco Perpetual High Income Fund for the sale of 5,917,160
ordinary shares of Alkermes at a price of $42.25 per share through a
registered direct offering, representing approximately 4% of Alkermes’
fully diluted shares outstanding. The transaction is expected to provide
gross proceeds of $250 million to Alkermes before deducting costs
associated with the offering. These proceeds will be used for general
corporate purposes. The parties expect to close the transaction on or
about Jan. 16, 2014.
The ordinary shares offered by Alkermes in this transaction will be
issued pursuant to its existing shelf registration statement on Form
S-3, which was declared effective by the Securities and Exchange
Commission (SEC) on Nov. 12, 2013, and is available on the SEC’s website
at www.sec.gov.
Ondra Partners provided advisory services to Alkermes in connection with
this transaction.
Copies of the prospectus and the accompanying base prospectus relating
to this sale may be obtained by request to: Alkermes plc, Attn:
Corporate Communications Department, 852 Winter Street, Waltham, MA
02451.
This press release shall not constitute an offer to sell, nor the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any state or jurisdiction.
About Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical company
that applies its scientific expertise and proprietary technologies to
develop innovative medicines that improve patient outcomes. The company
has a diversified portfolio of more than 20 commercial drug products and
a substantial clinical pipeline of product candidates that address
central nervous system (CNS) disorders such as addiction, schizophrenia
and depression. Headquartered in Dublin, Ireland, Alkermes plc has an
R&D center in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and manufacturing facilities in
Gainesville, Georgia and Wilmington, Ohio.
Note Regarding Forward-Looking Statements
Certain statements set forth above may constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Although the company believes that such statements
are based on reasonable assumptions within the bounds of its knowledge
of its business and operations, the forward-looking statements are
neither promises nor guarantees. The company's business and the other
matters discussed by such forward-looking statements are subject to
significant risk and uncertainties, and there can be no assurance that
actual results or events will not differ materially from its
expectations. These risks and uncertainties include the risks described
in the company's filings with the SEC and which are available at the
SEC's website at www.sec.gov.
The information contained in this press release is provided by the
company as of the date hereof and, except as required by law, the
company disclaims any intention or responsibility for updating any
forward-looking information contained in this press release.
Source: Alkermes plc
Alkermes
For Investors:
Rebecca
Peterson, +1-781-609-6378
or
For Media:
Jennifer Snyder,
+1-781-609-6166